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Abstract
We report the case of a 38-year old woman affected by primary lymphoma of the right breast, with
disease progression after chemotherapy and subsequent radiotherapy, successfully treated with a
modified radical mastectomy. The literature of primary breast lymphomas has been reviewed and
discussed in relation to our case. Our experience stresses the importance of a radical surgical
approach in a locally advanced non-Hodgkin's lymphoma of the breast unresponsive to radio and
chemotherapy.
Background
Primary lymphoma of the breast (PBL) is a rare disease
and all published series include a small number of
patients. We present the case of a 38-year old woman with
a primary non-Hodgkin lymphoma of the right breast
who was unsuccessfully treated by primary chemo and
radiotherapy. The patient was then referred to our Depart-
ment of General Surgery and Surgical Oncology and
treated with a modified radical mastectomy which
allowed complete removal of the tumor and local control
of the disease.
We report this case of a locally advanced PBL not respon-
sive to chemo and radiotherapy in order to emphasize the
role of the surgical approach in this subset of patients.
Case presentation
A 38-year-old woman was admitted to our hospital in July
2004 presenting a right breast mass. A physical examina-
tion revealed an elastic and mobile mass occupying the
upper quadrants of the right breast. Examination of the
axilla and neck was negative for enlarged lymph nodes.
Mammography showed a large mass of the right breast
with multiple opacities in its contest. Breast ultrasonogra-
phy (US) confirmed the presence of a hypervascularized
non-homogeneous mass with ill-defined margins (Figure
1). A percutaneous aspiration citology (FNAC) was per-
formed but resulted negative for malignant cells. The mass
showed a rapid growth and a second FNAC diagnosed a
diffuse large B-cell lymphoma (DLBCL) with a prolifera-
tion rate of more than 90%. Immunostaining profile by
monoclonal and polyclonal antibodies showed positivity
for CD5, CD20, Bcl 2, Bcl 6 and MUM1 and absence of
staining for CD10 and Cycline D. A thoracic and abdom-
inal computed tomography (CT-scan) confirmed the pres-
ence of the large breast mass associated with pathological
enlarged lymph nodes in the right axilla (Figure 2). A
bone-marrow biopsy resulted negative for lymphomatous
infiltration. The patient was diagnosed as stage IE accord-
ing to the Ann Arbor staging system and it was graded into
the low risk group with an IPI score of 1 [1,2].
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PBL is considered a disease with potential systemic diffu-
sion, to which primary chemo and radiotherapy are pres-
ently considered the most effective therapeutic approach.
Since the addition of Rituximab (R), a monoclonal anti-
body anti-CD20, showed an improvement of results in
the first line treatment of DLBCL, we treated the patient
with the immunochemiotherapy schedule R-CHOP
(Rituximab  375 mg/m2, Cyclophosphamide  750 mg/m2,
Vincristine 1,4 mg/m2, Doxorubicin 50 mg/m2, Prednisone
60 mg/m2), recycled every 3 weeks for 6 cycles. Although
a CT scan after the third cycle demonstrated a reduction of
the tumour mass of about 85%, which remained stable
until the end of the chemotherapy, a rapid growth of the
residual mass was showed already one month later.
A second-line polichemotherapy with HAM schedule
(high dose of Cytosine Arabinoside 6 g/m2 and Mitoxantrone
12 mg/m2) was then performed in January 2005. How-
ever, the breast lesion showed further progression one
month after. The systemic staging of disease by PET-TC
excluded distant localizations of the disease. In March
2005 the patient received radiotherapy (44 Gy) on the
right breast and omolateral axilla, obtaining disease stabi-
lization, but local relapse was noted 3 months later and a
PET/CT scan demonstrated enlarged right axillary lymph
nodes (Figure 3).
The patient was then referred to our Department for surgi-
cal evaluation. Despite the breast mass occupied whole
the upper and external quadrants of the right breast, it was
mobile on the underlying muscular layers. Enlarged
lymph nodes were palpable in the right axilla. We there-
fore performed a right modified radical mastectomy, with
sparing of the pectoral muscles, completed with a level III
axillary lymphadenectomy in order to remove the
enlarged axillary lymph nodes.
The surgical specimen was examinated by an expert
pathologist and the histological response confirmed the
diagnosis of DLBCL without skin, nipple, areola and mus-
cle wrap involvement. Seventeen axillary lymph nodes
examinated were not involved by tumour cells. The post-
operative course was uneventful and on second postoper-
ative day the patient was discharged.
At present, four and three years respectively later the med-
ical and surgical approach, the patient is disease free at
clinical and instrumental follow up.
Discussion
Non-Hodgkin lymphomas of the breast are uncommon
cancers which occur either as primary extranodal diseases
or as secondary localizations of a systemic disease. PBLs
have a reported incidence ranging from 0.04% to 0.5% of
all breast malignancies [3,4]. PBLs account for less than
1% of all patients with non-Hodgkin's lymphomas and
approximately for 1.7% of all extranodal non-Hodgkin's
lymphomas [3,4].
The criteria for the diagnosis of primary breast lymphoma
were suggested by Wiseman and Liao in 1972 and include:
(a) adequate pathologic evaluation, (b) close association
between lymphomatous infiltrate and mammary tissue
and (c) exclusion of either systemic lymphoma or
extramammary lymphoma, except simultaneous ipsilat-
Breast ultrasonography (US) shows the presence of a hyper- vascularized non-homogeneous mass with ill-defined margins Figure 1
Breast ultrasonography (US) shows the presence of a hyper-
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eral axillary node involvement [5]. Patients with breast
involvement as a result of progression or relapse of a pre-
viously diagnosed non-Hodgkin's lymphoma are consid-
ered as secondary breast lymphomas.
Available information regarding PBL are difficult to ana-
lyze and to compare because of the relatively small
number of patients in most series and the substantial dif-
ferences in criterions of classification that has been used,
such as lymphoma subtypes, histopatologic terminology,
treatment modalities and staging systems. Moreover,
A PET-CT shows a local relapse of disease Figure 3
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some among larger reports have also included secondary
breast lymphoma [4]. Overall, the characteristics of this
disease, such as natural history, prognostic factors and
impact of treatment have not been yet well established.
Most studies reported a preponderance of right-sided
presentation in breast lymphoma, but others reported the
opposite [6,7]. Bilaterality has been reported to occur in
1% to 14% of cases [6]. The incidence of breast lym-
phoma in men is extremely low [8].
Breast lymphoma and carcinoma usually have a similar
clinical and radiological presentation. Patients presenting
such of these malignancies generally refer to physician for
a painless enlarging breast mass.
Both lymphoma and carcinoma of the breast are diseases
of the middle-aged and elderly, although a small subset of
lymphomas (Burkitt's or Burkitt-like lymphomas)
presents at a young age, typically with bilateral involve-
ment and rapid progression. The reported median age for
breast lymphoma ranges from 51 to 60 years, but with a
wide range [6,7].
Even if breast lymphomas generally present no calcifica-
tions on mammograms [9], at present there are no clinical
or radiological findings which allow a differential diagno-
sis between lymphoma and carcinoma of the breast. The
cornerstone of the diagnostic process remains tissue
biopsy and histopathologic examination with appropriate
immunophenotyping.
In our case the patient showed an atypical presentation
with a clinical diffuse involvement of the right breast,
probably due to coexisting mastitis.
In our experience, fine needle aspiration cytology (FNAC)
resulted a reliable diagnostic technique, in accordance
with the high sensitivity reported in literature ranging
from 83% to 100% [10].
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon histological subtype, representing 45% to 79% of all
PBL cases [6,7].
Reported 5-year overall survival rates have varied from 9%
to 85% [6,11,12]. Tumor size, bilateral presentation and
axillary lymph node involvement are reported not to
affect the prognosis, while an important prognostic factor
is the histologic type of PLB in association with its tumor
grading and stage [6].
The therapeutic management is controversial and is not
fully established as yet. The frequency of surgery has been
declining since 1990 and this approach is presently not
indicated neither in case of lesions unresponsive to
chemo and radiotherapy nor for relapsing disease. Surgi-
cal treatments are seldom reported in literature, although
radical approaches have been abandoned on behalf of less
invasive treatments [13,14].
Combined radiation and chemotherapy seems to be the
most effective treatment, even in the early stages of PBL
[6,13,14]. Most authors suggest that chemotherapy and
radiotherapy should be the initial, and in most cases the
only treatment. Indeed, the number of patients success-
fully treated by a combination of chemotherapy and radi-
ation therapy has been increasing in recent years and this
approach has been proposed as the gold standard treat-
ment for PBL [6,13,14].
We reported a particular case of local advanced PLB that
showed a very poor response to systemic therapy. In fact,
our case had demonstrated a lack response either to the
first line chemotherapy protocol and to subsequent sal-
vage chemotherapy. The patient has been then unsuccess-
fully treated with radiotherapy, demonstrating further
increase of the mass which virtually occupied the whole
breast at the time of referral to our attention.
Surgical approach by radical mastectomy allowed
removal of the lesion with free margins and resulted in
optimal control of the disease, with the patient alive with-
out relapse at 36 months from surgery. Axillary lym-
phadenectomy was associated because of lymph nodes
clinically involved. However, in agreement with other
authors [13], we do not consider axillary lymph nodes dis-
section necessary. Indeed, the reported incidence of
involvement of the lymph nodes among PBL patients
ranges between 40 and 50% [13], but there is no evidence
that axillary clearance may improve the long term out-
come.
Even if several authors argue that mastectomy is not nec-
essary and most advocate systemic chemotherapy as the
proper treatment, further investigation on PLB is required
to define reliable prognostic factors and optimal manage-
ment and based on our experience we suggest that radical
surgery is an effective and safe option in those cases not
responsive to chemo-radiotherapy.
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